APR-246 + azacitidine

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)NCT03745716Aprea TherapeuticsPhase 3Completed2020-11-27Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.